Open access peer-reviewed chapter

Contemporary Surgical Management of Acute Massive Pulmonary Embolism

By Dawn S. Hui and P. Michael McFadden

Submitted: June 7th 2012Reviewed: October 1st 2012Published: June 12th 2013

DOI: 10.5772/53969

Downloaded: 2100

1. Introduction

Pulmonary embolism (PE) is the most lethal pulmonary condition in the United States and internationally. It is also the third most common cause of death in hospitalized patients. Since the introduction of computed tomographic pulmonary angiography (CT-PA), the estimated incidence of PE has risen from 62.1 to 112.3 cases per 100,000 [1]. Untreated, the associated mortality of PE is as high as 30% with recurrent embolism being the most common cause. Globally, systemic anticoagulation is the mainstay of treatment for both chronic and acute PE. In the case of acute massive PE (presenting with hypotension and systolic arterial pressure less than 90 mm Hg) the prognosis is much graver and associated with a mortality of 30-60%, second only to sudden cardiac death as a cause of sudden death. This condition mandates a more aggressive and urgent algorithm for diagnosis and treatment. Prompt and appropriate treatment, which may include surgical pulmonary embolectomy, can be life-saving.


2. Historical developments

The history of venous thrombosis and PE is intertwined with landmark developments in the disciplines of anatomy, pathology, hematology, and surgery [2]. While pathologic observations of postmortem pulmonary thrombi were detailed by Morgagni [3], Laennec [4], and Cruveilhier [5] in the 18th and 19th centuries, it was not until the late 19th century that the concept of thromboembolism was by recognized by Virchow. Virchow wrote “A plug may extend into the vena cava as thick as the last phalanx of the thumb. These are the thrombi that constitute the source of real danger; it is in them that ensues the crumbling away which leads to secondary occlusion in remote vessels” [6]. He was thus the first to ascribe a single pathophysiologic mechanism to these anatomically separate phenomena (Figures 1 and 2).

Figure 1.

Autopsy photo demonstrating a sudden fatal saddle embolism which occurred six days following pulmonary lobectomy.

The surgical treatment of pulmonary embolism was first proposed by Friedrich Trendelenburg, a German professor of surgery from Leipzig. Having studied the cases of nine patients who died from acute pulmonary embolism, he developed a technique of pulmonary embolectomy through animal experimentation. His first two human patients died at 15 hours and 37 hours, from heart failure and hemorrhage of the internal mammary artery respectively [7]. Trendelenburg’s student Martin Kirschner reported the first successful pulmonary embolectomy to the German Surgical Conference in Berlin in 1924 [8]. In Europe this became a popular emergent bedside operation for patients in whom PE was strongly suspected. Surgical residents were relegated to a bedside vigil and watched for sudden circulatory collapse and respiratory compromise in high-risk patients. Fewer than 10 patients survived the operation in 300 cases over a decade [2]. Though popular in Europe, the first successful pulmonary embolectomy was not reported in the United States until 1958 [9]. Operative mortality was frequently due to myocardial ischemia resulting in ventricular fibrillation and death at anesthetic induction [10]. The development of extracorporeal circulation by John Gibbon was in fact stimulated by his reflections while keeping vigil over a patient who underwent an unsuccessful attempt at pulmonary embolectomy: “…During the hours that night, John watched the patient’s distended veins and recorded the faltering pulse, respirations and blood pressure, the thought occurred to him and constantly recurred to him that her conditions could surely be improved if only there were some form of continuously withdrawing some of the blue blood from the swollen veins into an apparatus where the blood could pick up oxygen and discharge carbon dioxide, and then be pumped back into the patient’s arteries” [11]. This stimulated his work over the next twenty years to develop the heart-lung machine, ultimately opening the doors to modern cardiac surgery and to the first successful pulmonary embolectomy on cardiopulmonary bypass (CPB) by Edward Sharp in 1962 [10].

Figure 2.

The saddle embolism isolated

Other surgical developments benefited from Virchow’s legacy by attacking the problem at its more proximate source. The American surgeon Alton Ochsner, who had been present at Kirschner’s 1924 address, proposed with Michael DeBakey to ligate the IVC in 1932 [12, 13]. John Homans, a general surgeon focused on venous disease, performed prophylactic lower extremity vein ligation [14]. Caval interruption commonly resulted in chronic lower extremity edema with the complications of varices, edema, and ulceration. As Spencer stated, “Because of the morbidity often following ligation of the vena cava, it is probably used too seldom and too late, being reserved as last resort...” [15]. Narrowing of the IVC via a right flank incision as an adjunct to pulmonary embolectomy has also been described, with the authors abandoning this technique due to impaired venous return [16]. Refinement of venous interruption came in the form of the Miles clip [17], partial caval plication, and finally percutaneous intraluminal occlusive devices (Figure 3). Early occlusive devices were hampered by complications of migration, embolization, vena cava wall rupture, and the need for femoral cutdown. Current filters have evolved in ease of insertion, lower complication rates, and efficacy with long-term patency rates of 98% and 3% recurrent embolism rates [18,19] (Figure 4).

Figure 3.

Vena Cava Filter.

Figure 4.

Nitinol OptionTM Vena Cava Filter (Argon Medical Devices, Plano, TX). Features of contemporary filters include retrievability, MRI compatibility, and percutaneous insertion.

Concurrent with the developments in surgical techniques to treat PE were discoveries in anticoagulation. Heparin, discovered by McLean [20] and validated by Murray [21], has become the workhorse of initial therapy of PE. The discovery of oral dicumerol in the 1940s has led to the use of anticoagulation as the mainstay of both prevention of and therapy for venous thrombosis and PE. The efficacy of anticoagulants, thrombolytics, and vena caval filters combined with the high mortality rate of pulmonary embolectomy, had led to a paradigm shift towards nonoperative management of acute massive PE.

3. Contemporary management: diagnosis and prognostication

Classification of PE was historically based on the angiographic burden, using the Miller Index [22]. Current classification by American Heart Association differentiates between massive PE (sustained hypotension for at least 15 minutes or requiring inotropic support, pulselessness, or persistent profound bradycardia) from submassive (acute PE without systemic hypotension but with either RV dysfunction or myocardial necrosis) (Table 1) [23]. Early identification and risk stratification is mandatory at the time of diagnosis in order to coordinate multimodality treatment strategies. Prompt diagnosis and initiation of treatment can reverse RV failure and reduce mortality. Current tools for prognostication include clinical parameters, radiographic findings, and laboratory markers.

Massive PEAcute PE with sustained hypotension (Systolic blood pressure <90 mm Hg for at least 15 minutes or requiring inotropic support)
Not due to a cause other than PE, such as arrhythmia, hypovolemia, sepsis, or left ventricular [LV] dysfunction
Persistent profound bradycardia (heart rate<40 bpm with signs or symptoms of shock)
Submassive PEAcute PE without systemic hypotension (systolic blood pressure <90 mm Hg) but with either right ventricular (RV) dysfunction or myocardial necrosis
RV dysfunction means the presence of at least 1 of the following:
RV dilation (apical 4-chamber RV diameter divided by LV diameter > 0.9) or RV systolic dysfunction on echocardiography
RV dilation (4-chamber RV diameter divided by LV diameter > 0.9) on computed tomography
Elevation of beta-natriuretic peptide (BNP >90 pg/mL)
Elevation of N-terminal pro-BNP (> 500 pg/mL)
Electrocardiographic changes (new complete or incomplete right bundle-branch block, anteroseptal ST elevation or depression, or anteroseptal T-wave inversion)
Myocardial necrosis is defined as either of the following:
Elevation of troponin I (>0.4 ng/mL) or
Elevation of troponin T (>0.1 ng/mL)

Table 1.

American Heart Association Classification of Pulmonary Embolism [23].

Clinical signs consistent with major PE include transient syncope, cyanosis, elevated jugular venous pressure, tachypnea, unilateral restriction of chest wall movement, fever, and signs of RV dysfunction (Table 2).

Clinical Signs of RV dysfunctionLeft parasternal heave
Accentuated P2
Murmur of tricuspid regurgitation
Distended neck veins
Unilateral restriction of chest wall
Electrocardiogram Signs of
Right Heart Strain
Right axis deviation
T-wave in V1-V4
Qr pattern in V1
P2 = pulmonic second heart sound
RBBB = right bundle branch block
RV = right ventricle

Table 2.

Clinical and Electrocardiographic Signs of RV dysfunction [24]

Several scoring systems including the Pulmonary Embolism Severity Index [25] and Revised Geneva Score [26] have been developed based primarily on clinical signs and history (Tables 3 & 4). They have been shown to have prognostic value [23] and do not require diagnostic studies, making them a valuable tool for early prognostication.

Pulmonary EmbolismSeverity IndexScore
Age1 point per year
Male Sex10
History of Cancer30
History of Heart Failure10
History of Chronic Lung Disease10
Pulse > 110 beats/min20
Systolic Blood Pressure < 100 mm Hg30
Respiratory Rate > breaths/min20
Temperature < 35 ˚C20
Altered Mental Status60
Arterial oxyhemoglobin saturation level <90%20
ClassMortality Risk
Class I - < 65 points0 - 1.6%
Class II - 65-85 points1.7 - 3.5%
Class III - 85-105 points3.2 - 7.1%
Class IV - 106-125 points4.0 - 11.4%
Class V - >125 points10.0 - 24.5%

Table 3.

Pulmonary Embolism Severity Index [25]

Revised Geneva ScorePoints
Age > 65 years1
Previous DVT or PE3
Surgery under general anesthesia or lower limb fracture within 1 month2
Active malignant condition (solid or hematologic, currently active or considered cured < 1 year)2
Unilateral lower limb pain3
Heart rate 75-94 beats/min3
Heart rate > 94 beats/min5
Pain on lower limb deep venous palpation and unilateral edema4
Clinical Probability
Low: 0 - 3 points
Intermediate: 4-10 points
High: >10 points

Table 4.

Revised Geneva Score [26]

Biomarkers assessing the degree of right ventricular dysfunction associated with massive PE that have been studied include troponin and beta-natriuretic peptide (BNP). Right ventricular strain results in elevated troponin levels through acute shear stress causing microinjury and microinfarction, as well as increased oxygen demand and diminished perfusion from an acutely dilated and overloaded RV. Troponin levels have been found to correlate with the presence of RV dysfunction [27,28], and cutoff values for troponin prognostication in PE are identical to those in acute MI [29] while cutoff values for BNP are lower than those in congestive heart failure. Negative predictive value for both troponin and BNP are 97-100%; however the positive predictive values are low, with a wide range of sensitivities and low specificity for adverse events.

While most patients with suspected PE will have computed tomography angiography of the chest, on occasion concerns for acute renal injury will prompt workup with ventilation-perfusion scans. RV enlargement, defined as RV to LV dimension ratio > 0.9 on a reconstructed CT 4-chamber view, has been found to correlate with echocardiographic findings of RV dysfunction [30]. Subsequently, a study of 431 consecutive patients with acute PE found that RV enlargement predicted 30-day mortality (15.6% vs 7.7%, hazard ratio 5.17) as well as the composite end-point of death and in-hospital complications [31]. Dynamic CT assessment of right ventricular response to reperfusion therapy or surgical embolectomy found that although RV enlargement persisted in 43%, significant reductions in mean RV dimension and RV/LV ratio and significant increases in mean LV occurred with therapy, and did so equally in patients treated with thrombolysis versus embolectomy. Patients presenting with cardiogenic shock had a greater degree of initial RV enlargement and a greater reduction post-therapy [32]. Echocardiography may demonstrate the McConnell sign of acute pulmonary embolism, a characteristic pattern of akinesis of the mid free wall and normal motion of the apex [33]. Other signs include right ventricular hypokinesis, right ventricle dilation, and signs of pulmonary hypertension. In normotensive patients, RV dilation is present in 30-40% and predicts in-hospital mortality as well higher non-resolution and recurrence of pulmonary thrombus burden [34].

4. Contemporary multimodality management

While chronic conditions such as heart failure and malignancy are responsible for most of the late deaths in acute PE, early 30-day mortality results primarily from right ventricular failure [31]. Contemporary diagnostic modalities such as computed tomography and echocardiography allow for improved risk stratification and patient selection for pulmonary embolectomy, while evolution of surgical techniques has prompted a renewed enthusiasm for surgical pulmonary embolectomy as part of a multimodality approach to massive acute PE (Figure 5). The indications for open surgical embolectomy have traditionally been for clearly documented acute massive pulmonary embolism with persistent hypotension refractory to maximal pharmacological support.

Figure 5.

Contemporary multimodality approach to treatment of acute massive PE

Multimodality treatment begins with immediate systemic heparinization at diagnosis, cardiogenic support with inotropic agents and vasopressors as indicated, and correction of hypoxemia with supplemental oxygen or ventilatory support with pulmonary arterial vasodilation using inhaled nitric oxide. The underlying critical pathology is acutely elevated pulmonary vascular resistance (PVR) leading to pressure overload of the right ventricle and acute RV distention. Through ventricular interdependence, LV filling is reduced, compromising cardiac output and oxygen delivery. (Figure 6). The initial goals of medical management are optimization of RV preload and systolic function, reduction of pulmonary vascular resistance, and maintenance of right coronary perfusion pressure by adequate aortic root pressure [35]. Acute massive pulmonary embolism is initially a pressure overload problem of the RV. Higher filling pressures may be required; however an altered Frank-Starling curve in the setting of RV dysfunction may lead to volume overload as well. For patients with low cardiac output and normal blood pressure, modest fluid challenges may be beneficial, and the use of dobutamine and dopamine is a class IIa recommendation. Class I recommendations include correction of systemic hypotension and use of vasopressors, although the use of norepinephrine lacks clinical data, while the beneficial use of epinephrine in PE with shock has been reported [36].

Figure 6.

Hemodynamic effects of acute massive PE

RV function is coupled to pulmonary vascular resistance. Agents to reverse elevated PVR may be intravenous, inhaled, or oral. All intravenous forms (prostacyclin, iloprost, sildenafil, milrinone, and adenosine) carry the risk of systemic hypotension and should be instituted only after resuscitation and adequate perfusion of the RV. These agents may worsen the ventilation/perfusion ratio, increasing the degree of pulmonary shunt. Inhalational agents target the therapy to well-ventilated regions of the pulmonary bed, improving V/Q ratio and decreasing shunt fraction. Inhaled nitric oxide (iNO) has been studied in ARDS, pulmonary hypertension, and post mitral valve surgery, while evidence of its use in pulmonary embolism is limited to case reports and small case series. [37, 38, 39, 40]. While controlled studies supporting its routine use as an adjunct are lacking, anecdotal evidence based on timing of the institution of iNO seems to point to reductions in mean pulmonary artery pressures, increases in arterial oxygenation, and improvement in hemodynamics [38].

4.1. Surgical pulmonary embolectomy

The Trendelenburg operation was performed through a second transthoracic incision with resection of the second rib, occlusion of the aorta and pulmonary artery with an encircling rubber tube, and rapid removal of the embolism through a limited arteriotomy. Occlusion was limited to “forty-five seconds to two minutes, beyond that, death occurs” [7]. Modern surgical approach is by median sternotomy. After systemic heparinization, normothermic CPB is instituted via aortic and bicaval cannulation. The vena cavae are encircled with umbilical tapes. The operation is performed either with a beating heart and vacuum-assisted venous drainage or with the heart arrested. Deep hypothermic circulatory arrest has also been used in cases to optimize visualization for complete embolectomy [41]. The cavae are snared to isolate right heart inflow. A longitudinal incision of the pulmonary trunk is made two cm above the pulmonary valve. The extent of pulmonary arteriotomy is tailored to the location of thrombus. The incision can be carried in a hockey-stick fashion onto the left main pulmonary artery (Figure 7). For right-sided embolectomy, the right pulmonary artery is incised between the superior vena cava and the aorta. A variety of techniques of thrombus extraction have been described. Large clot can be retrieved with Randall stone forceps, vigorous suction, and Fogarty embolectomy catheters passed into branch arteries. Opening of the bilateral pleura and manual compression of the lungs to extrude peripheral clot has been described but has the drawbacks of mechanical injury to the arterial walls and lung parenchyma, as well as possibly causing endobronchial bleeding [42].

Retrograde flushing via direct cannulation of the pulmonary veins from the left atrium has been described to remove not only residual thrombotic material but air embolism as well. As described by Zarrabi et al, if the right atrium is opened to look for suspected clot, a septal incision through the fossa is then made, the left atrium entered, and the pulmonary veins identified. A cannula is attached to the pump oxygenator, inserted into each pulmonary vein sequentially, and flushed for 60-80 seconds with a mean pressure of 15-17 mm Hg. Clot and debris thus flushed retrograde through the pulmonary veins is extracted through the pulmonary arteriotomy [43]. If the right atrium is not entered, retrograde flushing of the left atrium can be performed via a 20 Fr cannula. This is inserted through the right superior pulmonary vein and attached to the arterial line through a Y connector [44]. Finally, adequate visualization of the distal arterial tree can be extended with use of an arterioscope. Postoperative mortality in these patients is felt to be due to eventual right ventricular failure from residual thrombus causing persistent pulmonary hypertension and interstitial pulmonary edema [41]. However, data concerning which of the above techniques is best to remove thrombus burden in the lungs, reduce RV strain, or improve outcomes is lacking. Intraoperative use of TEE during pulmonary embolectomy is recommended and can identify intrathoracic extrapulmonary thromboemboli which may alter planned surgical maneuvers [45]. Reflecting back towards the original Trendelenburg procedure, inflow occlusion pulmonary embolectomy is an option where CPB is not immediately available. This technique consists of caval occlusion for 3-minute maximal periods, beyond which there is great risk of cardiac and neurologic complications [46].

Figure 7.

Technique of cardiopulmonary bypass with bicaval cannulation, arrows indicating direction of blood flow. Randall stone forceps are inserted through the main pulmonary arteriotomy to extract a portion of embolus from the left pulmonary artery. Inset: The three arteriotomy sites: main pulmonary artery, left and right pulmonary arteries

4.2. Contemporary surgical outcomes and expanded indications

A systematic review of pulmonary embolectomies in the period from 1961 to 2006 showed the average mortality to be 30%. Several important factors in mortality included the time period, with higher mortality reported in studies before 1985 (32% vs 20%) and in patients with preoperative cardiac arrest (59% vs 29%) [47]. Prospectively studied patients that have failed an initial course of thrombolytics have lower mortality with embolectomy than with a second course of thrombolysis (7% vs. 38%) [48]. More recent studies have begun to examine results in patients not meeting strict criteria of sustained hypotension or cardiogenic shock, but rather using evidence of RV dysfunction as an expanded criteria for pulmonary embolectomy, with operative mortality in contemporary series being 6-8% [49-53]. Expediency of operation has also found to have improved outcomes, particularly with surgical therapy occurring within 24 hours of diagnosis [54]. The improvement in operative mortality in the modern era may be due to several factors: improved patient selection, early identification of RV dysfunction with contemporary diagnostic modalities, extent of pulmonary thrombectomy to prevent residual thrombus and thus pulmonary hypertension, the prophylactic use of IVC filters, and early operation before the development of cardiogenic shock or the need for cardiopulmonary resuscitation, both of which confer a significantly increased in-hospital mortality (25% and 65%, respectively vs 8.1%) [55]. By instituting a criteria of RV dysfunction as an indication for pulmonary embolectomy, the population to be considered expands to include patients with submassive PE.

4.3. Thrombolytics, special populations, catheter-based therapy, and IVC filters

The benefit of thrombolytic therapy in the treatment of acute PE has been controversial. A meta-analysis showed that overall, there was no significant reduction in PE or death when comparing thrombolysis with heparin; neither was the risk of major bleeding significantly increased. Subgroup analysis showed a significant reduction in PE and death in the trials that included patients with major (i.e. hemodynamically unstable) PE and no benefit in those trials that excluded those patients [56]. A review of current evidence concluded that, “Despite the lack of a verifiable mortality benefit associated with thrombolytic therapy in patients with massive PE resulting in hemodynamic instability, most clinicians accept this clinical scenario as indication for thrombolytics and it is guideline based” [57]. In the most recent guidelines (2012), The American College of Chest Physicians evidence for thrombolytic administration is graded 2C for unstable patients without high bleeding risk; recommendations are against thrombolytics in stable patients (Grade 1C) [58].

Because the effects are systemic, thrombolytics poses a risk of serious perioperative bleeding and should be approached with caution in patients with acute massive PE that may be considered for surgical embolectomy.

This decision is of particular interest in populations whose underlying disease places them at increased risk of bleeding elsewhere. Trauma patients with immobility and/or traumatic brain injury are prone to DVT and PE; sites of bleeding risk include concomitant solid organ injury and intracranial hemorrhage. Reluctance to place prophylactic IVC filters has been due to filter-related complications and inconsistent follow-up; this has been tempered by more recent studies showing low complication rates and safe retrievability at greater intervals. Limited data consisting of matched-control trials have shown reduced PE and PE-related mortality rates with prophylactic filters [59]. Yet, prophylactic IVC filter placement in at-risk patients remains a Level III recommendation by the Eastern Association for the Surgery Trauma guidelines [60]. Increased risk of both thromboembolic disease and intracranial hemorrhage is seen also in patients with brain tumors. Successful pulmonary embolectomy has been reported in a patient with advanced glioblastoma multiforme, suggesting that this clinical scenario may represent an extended indication for surgery [61]. In patients with significant cardiac disease, pulmonary symptoms are often ascribed to cardiac etiology, but rarely concomitant PE may be discovered [62], in which case surgical pulmonary embolectomy may be combined with the operation to treat the primary cardiac disease.

Catheter-based techniques include aspiration thrombectomy, fragmentation, and rheolytic thrombectomy. Rheolytic thrombectomy using the AngioJet and Rotarex devices has been shown to be technically feasible with success rates of 92.2% to 100%, with significant improvements in both angiographic indices and clinical indices (i.e, Miller Index, obstruction index, perfusion index, mean pulmonary artery pressures, partial arterial pressures) [63, 64]. Data is limited to small series, and this therapy requires experienced laboratories. Its role as primary therapy is for patients with contraindications to thrombolysis, failed thrombolysis, or impending death from shock prior to thrombolysis when no other intervention is available [58].

The placement of IVC filters is prudent even after treatment with pulmonary embolectomy to prevent recurrent embolism from lower extremity sources. In several series, this has resulted in a zero recurrence rate [53, 65], while a 23% recurrence rate was noted in a series of patients without IVC filter placement after embolectomy [48].

5. Conclusion

Acute massive pulmonary embolism is a disease best treated by multimodality therapy, beginning with systemic heparinization and IVC filter placement. A multitude of diagnostic modalities, including transesophageal echocardiography and computed chest tomography, are available in the contemporary setting to guide risk-stratification and to assess RV dysfunction. Contemporary series of pulmonary embolectomy have demonstrated low operative mortality with improved surgical techniques, and survival is increased when operative therapy occurs before the development of hemodynamic collapse. Thus, the modified Trendelenburg procedure with extended distal pulmonary embolectomy should be part of an aggressive approach to an otherwise lethal problem in the current age.

© 2013 The Author(s). Licensee IntechOpen. This chapter is distributed under the terms of the Creative Commons Attribution 3.0 License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

How to cite and reference

Link to this chapter Copy to clipboard

Cite this chapter Copy to clipboard

Dawn S. Hui and P. Michael McFadden (June 12th 2013). Contemporary Surgical Management of Acute Massive Pulmonary Embolism, Principles and Practice of Cardiothoracic Surgery, Michael S. Firstenberg, IntechOpen, DOI: 10.5772/53969. Available from:

chapter statistics

2100total chapter downloads

More statistics for editors and authors

Login to your personal dashboard for more detailed statistics on your publications.

Access personal reporting

Related Content

This Book

Next chapter

Anesthesia for Thoracic Surgical Procedures

By January Tsai, Teresa Moon, Shital Vachhani, Javier Lasala, Peter H Norman and Ronaldo Purugganan

Related Book

First chapter

Introductory Chapter: Evolution of ECMO from Salvage to Mainstream Supportive and Resuscitative Therapy

By Michael S. Firstenberg

We are IntechOpen, the world's leading publisher of Open Access books. Built by scientists, for scientists. Our readership spans scientists, professors, researchers, librarians, and students, as well as business professionals. We share our knowledge and peer-reveiwed research papers with libraries, scientific and engineering societies, and also work with corporate R&D departments and government entities.

More About Us